Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Debt-to-Equity : -0.40 (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Provectus Biopharmaceuticals Debt-to-Equity?

Provectus Biopharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.00 Mil. Provectus Biopharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.03 Mil. Provectus Biopharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-7.59 Mil. Provectus Biopharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was -0.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Provectus Biopharmaceuticals's Debt-to-Equity or its related term are showing as below:

PVCT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.94 Med: -0.79 Max: -0.35
Current: -0.4

During the past 13 years, the highest Debt-to-Equity Ratio of Provectus Biopharmaceuticals was -0.35. The lowest was -0.94. And the median was -0.79.

PVCT's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs PVCT: -0.40

Provectus Biopharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Provectus Biopharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provectus Biopharmaceuticals Debt-to-Equity Chart

Provectus Biopharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.86

-0.79

-0.42

-0.35

-0.40

Provectus Biopharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-0.35	-0.38	-0.39	-0.42	-0.40

Competitive Comparison of Provectus Biopharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Provectus Biopharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Provectus Biopharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's Debt-to-Equity falls into.

Provectus Biopharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Provectus Biopharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.001	+	0.025)	/	-7.593
	=	-0.40

Provectus Biopharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.001	+	0.025)	/	-7.593
	=	-0.40

Provectus Biopharmaceuticals (OTCPK:PVCT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Provectus Biopharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provectus Biopharmaceuticals Inc (OTCPK:PVCT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

800 S Gay St, Suite 1610, Knoxville, TN, USA, 37932

Website

https://www.provectusbio.com

Provectus Biopharmaceuticals Inc is a is a clinical-stage biotechnology company. It is engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The company has developed and intends to license or market and sell its two prescription drug candidates, PV-10 and PH-10. Its PV-10 is for the treatment of several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The PH-10 is to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema.

Executives

Jeffrey Allen Morris	10 percent owner	1729 TRIANGLE PARK DR., MARYVILLE TN 37801
Webster Bailey	director	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Heather Raines	officer: Chief Financial Officer	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Edward Pershing	director	2220 SOUTHERLAND AVE, KNOXVILLE TN 37919
John Iii Lacy	director	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
John R Glass	officer: See Remarks	7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931
Bruce Horowitz	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Dominic Rodrigues	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Peter R Culpepper	officer: Interim CEO, CFO, COO	7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931
Eric Phd Wachter	director, officer: Chief Technology Officer	PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Jan Koe	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Smith Alfred E. Iv	director	191 MAIN STREET, NEW CANAAN CT 06840
Kelly M Mcmasters	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Donald E Adams	10 percent owner	370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401
Timothy Phd Scott	director, 10 percent owner, officer: President	PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931